Next Article in Journal
Circulating Tumor DNA as a Complementary Prognostic Biomarker during CAR-T Therapy in B-Cell Non-Hodgkin Lymphomas
Previous Article in Journal
Integrating Imaging and Circulating Tumor DNA Features for Predicting Patient Outcomes
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Retraction

RETRACTED: Godugu et al. Anti-Cancer Activities of Thyrointegrin αvβ3 Antagonist Mono- and Bis-Triazole Tetraiodothyroacetic Acid Conjugated via Polyethylene Glycols in Glioblastoma. Cancers 2021, 13, 2780

The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, NY 12208, USA
*
Author to whom correspondence should be addressed.
Cancers 2024, 16(10), 1880; https://doi.org/10.3390/cancers16101880
Submission received: 15 April 2024 / Accepted: 17 April 2024 / Published: 15 May 2024
The journal retracts the article, “Anti-Cancer Activities of Thyrointegrin αvβ3 Antagonist Mono- and Bis-Triazole Tetraiodothyroacetic Acid Conjugated via Polyethylene Glycols in Glioblastoma” [1].
During a recent investigation, the Albany College of Pharmacy and Health Sciences determined that multiple images were falsified or fabricated in this paper [1]. The misconduct findings are associated with the manipulation, re-use, and relabeling of images, and since the authors are members of Albany College, the college has requested the retraction of the article.
A correction [1] was submitted. However, the authors did not sufficiently explain the issues with the original images to the investigation committee, creating cause for concern regarding the validity of the experiments.
This retraction was approved by the Editor-in-Chief of the journal Cancers.
The authors did not agree with this retraction.

Reference

  1. Godugu, K.; Rajabi, M.; Mousa, S.A. RETRACTED: Anti-Cancer Activities of Thyrointegrin αvβ3 Antagonist Mono- and Bis-Triazole Tetraiodothyroacetic Acid Conjugated via Polyethylene Glycols in Glioblastoma. Cancers 2021, 13, 2780, corrected in Cancers 2022, 14, 5371. https://doi.org/10.3390/cancers14215371. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Godugu, K.; Rajabi, M.; Mousa, S.A. RETRACTED: Godugu et al. Anti-Cancer Activities of Thyrointegrin αvβ3 Antagonist Mono- and Bis-Triazole Tetraiodothyroacetic Acid Conjugated via Polyethylene Glycols in Glioblastoma. Cancers 2021, 13, 2780. Cancers 2024, 16, 1880. https://doi.org/10.3390/cancers16101880

AMA Style

Godugu K, Rajabi M, Mousa SA. RETRACTED: Godugu et al. Anti-Cancer Activities of Thyrointegrin αvβ3 Antagonist Mono- and Bis-Triazole Tetraiodothyroacetic Acid Conjugated via Polyethylene Glycols in Glioblastoma. Cancers 2021, 13, 2780. Cancers. 2024; 16(10):1880. https://doi.org/10.3390/cancers16101880

Chicago/Turabian Style

Godugu, Kavitha, Mehdi Rajabi, and Shaker A. Mousa. 2024. "RETRACTED: Godugu et al. Anti-Cancer Activities of Thyrointegrin αvβ3 Antagonist Mono- and Bis-Triazole Tetraiodothyroacetic Acid Conjugated via Polyethylene Glycols in Glioblastoma. Cancers 2021, 13, 2780" Cancers 16, no. 10: 1880. https://doi.org/10.3390/cancers16101880

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop